Viatris sells stake in Biocon Biologics for $815 million, regains global Biosimilars access

Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

Teva breaks ground with EU approval for two key bone disease biosimilars

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506

EMA grants GMP Certificate of compliance to CuraTeQ biosimilars’ Hyderabad facility

The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections

Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries

Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines